vs
Gen Digital（GEN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Gen Digital的季度营收约是Revvity的1.6倍（$1.2B vs $772.1M），Gen Digital净利率更高（15.5% vs 12.7%，领先2.7%），Gen Digital同比增速更快（28.5% vs 5.9%），过去两年Gen Digital的营收复合增速更高（13.2% vs 9.0%）
Gen Digital是一家跨国软件企业，双总部分别设于美国亚利桑那州坦佩和欧盟捷克布拉格，是财富500强企业及标普500指数成分股，同时在纳斯达克与布拉格证券交易所挂牌上市。公司主营网络安全软件、金融科技及相关服务，旗下拥有诺顿、Avast、LifeLock、AVG、CCleaner等多个知名品牌。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GEN vs RVTY — 直观对比
营收规模更大
GEN
是对方的1.6倍
$772.1M
营收增速更快
GEN
高出22.6%
5.9%
净利率更高
GEN
高出2.7%
12.7%
两年增速更快
GEN
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $192.0M | $98.4M |
| 毛利率 | 78.4% | — |
| 营业利润率 | 34.9% | 14.5% |
| 净利率 | 15.5% | 12.7% |
| 营收同比 | 28.5% | 5.9% |
| 净利润同比 | 6.1% | 3.9% |
| 每股收益（稀释后） | $0.31 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GENRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | — | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $986.0M | $729.4M | ||
| Q3 24 | $974.0M | $684.0M | ||
| Q2 24 | $965.0M | $691.7M |
净利润GENRVTY
| Q1 26 | $192.0M | — | ||
| Q4 25 | $134.0M | $98.4M | ||
| Q3 25 | $135.0M | $46.7M | ||
| Q2 25 | — | $53.9M | ||
| Q1 25 | $142.0M | $42.2M | ||
| Q4 24 | $159.0M | $94.6M | ||
| Q3 24 | $161.0M | $94.4M | ||
| Q2 24 | $181.0M | $55.4M |
毛利率GENRVTY
| Q1 26 | 78.4% | — | ||
| Q4 25 | 78.2% | — | ||
| Q3 25 | 78.8% | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | 80.3% | 56.5% | ||
| Q4 24 | 80.4% | — | ||
| Q3 24 | 80.1% | 56.3% | ||
| Q2 24 | 80.3% | 55.7% |
营业利润率GENRVTY
| Q1 26 | 34.9% | — | ||
| Q4 25 | 35.9% | 14.5% | ||
| Q3 25 | 35.5% | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | 41.3% | 10.9% | ||
| Q4 24 | 37.9% | 16.3% | ||
| Q3 24 | 41.3% | 14.3% | ||
| Q2 24 | 43.2% | 12.4% |
净利率GENRVTY
| Q1 26 | 15.5% | — | ||
| Q4 25 | 11.0% | 12.7% | ||
| Q3 25 | 10.7% | 6.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | 14.1% | 6.4% | ||
| Q4 24 | 16.1% | 13.0% | ||
| Q3 24 | 16.5% | 13.8% | ||
| Q2 24 | 18.8% | 8.0% |
每股收益（稀释后）GENRVTY
| Q1 26 | $0.31 | — | ||
| Q4 25 | $0.21 | $0.86 | ||
| Q3 25 | $0.22 | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | $0.22 | $0.35 | ||
| Q4 24 | $0.26 | $0.77 | ||
| Q3 24 | $0.26 | $0.77 | ||
| Q2 24 | $0.29 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $8.4B | — |
| 股东权益账面价值 | $2.3B | $7.3B |
| 总资产 | $15.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 3.61× | — |
8季度趋势，按日历期对齐
现金及短期投资GENRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $883.0M | $1.2B | ||
| Q3 24 | $737.0M | $1.2B | ||
| Q2 24 | $644.0M | $2.0B |
总债务GENRVTY
| Q1 26 | $8.4B | — | ||
| Q4 25 | $8.7B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $8.3B | — | ||
| Q4 24 | $8.5B | — | ||
| Q3 24 | $8.5B | — | ||
| Q2 24 | $8.5B | — |
股东权益GENRVTY
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.5B | $7.3B | ||
| Q3 25 | $2.4B | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | $2.3B | $7.6B | ||
| Q4 24 | $2.2B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B |
总资产GENRVTY
| Q1 26 | $15.8B | — | ||
| Q4 25 | $16.1B | $12.2B | ||
| Q3 25 | $16.4B | $12.1B | ||
| Q2 25 | — | $12.4B | ||
| Q1 25 | $15.5B | $12.4B | ||
| Q4 24 | $15.4B | $12.4B | ||
| Q3 24 | $15.5B | $12.8B | ||
| Q2 24 | $15.4B | $13.4B |
负债/权益比GENRVTY
| Q1 26 | 3.61× | — | ||
| Q4 25 | 3.54× | — | ||
| Q3 25 | 3.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.64× | — | ||
| Q4 24 | 3.94× | — | ||
| Q3 24 | 4.06× | — | ||
| Q2 24 | 4.33× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流GENRVTY
| Q1 26 | — | — | ||
| Q4 25 | $541.0M | $182.0M | ||
| Q3 25 | $409.0M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | $473.0M | $128.2M | ||
| Q4 24 | $326.0M | $174.2M | ||
| Q3 24 | $158.0M | $147.9M | ||
| Q2 24 | $264.0M | $158.6M |
自由现金流GENRVTY
| Q1 26 | — | — | ||
| Q4 25 | $535.0M | $161.8M | ||
| Q3 25 | $405.0M | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | $470.0M | $112.2M | ||
| Q4 24 | $318.0M | $149.8M | ||
| Q3 24 | $156.0M | $125.6M | ||
| Q2 24 | $262.0M | $136.6M |
自由现金流率GENRVTY
| Q1 26 | — | — | ||
| Q4 25 | 43.9% | 21.0% | ||
| Q3 25 | 32.2% | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | 46.5% | 16.9% | ||
| Q4 24 | 32.3% | 20.5% | ||
| Q3 24 | 16.0% | 18.4% | ||
| Q2 24 | 27.2% | 19.7% |
资本支出强度GENRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | 0.3% | 2.4% | ||
| Q4 24 | 0.8% | 3.4% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.2% | 3.2% |
现金转化率GENRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.04× | 1.85× | ||
| Q3 25 | 3.03× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 3.33× | 3.03× | ||
| Q4 24 | 2.05× | 1.84× | ||
| Q3 24 | 0.98× | 1.57× | ||
| Q2 24 | 1.46× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GEN
| Cyber Safety Platform | $819.0M | 66% |
| Trust Based Solutions | $421.0M | 34% |
| Net Interest Income On Notes Receivable | $4.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
